Although amyloid β (Aβ) is fundamental to Alzheimer’s disease (AD) pathology development, Aβ-lowering drugs failed in clinical trials, suggesting that additional amyloid precursor protein (APP)-dependent mechanisms might play an important role in AD pathogenesis. Here, APP is linked to Alzheimer disease.